Pieter J Visser

List of Publications by Year
in descending order

439 papers	34,114 citations	10986 71 h-index	4117 175 g-index
485 all docs	485 docs citations	485 times ranked	25504 citing authors

#	Article	IF	Citations
1	Mild cognitive impairment â€“ beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine, 2004, 256, 240-246.	6.0	4,039
2	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDSâ€“ADRDA criteria. Lancet Neurology, The, 2007, 6, 734-746.	10.2	3,755
3	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
4	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.8	1,863
5	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
6	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	7.4	1,009
7	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurology, The, 2009, 8, 619-627.	10.2	542
8	Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 714-718.	1.9	539
9	Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. NeuroImage, 2004, 23, 708-716.	4.2	522
10	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
11	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurology, The, 2013, 12, 957-965.	10.2	471
12	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	10.2	464
13	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
14	Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology, 2004, 63, 94-100.	1.1	307
15	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. Journal of Alzheimer's Disease, 2014, 41, 313-327.	2.6	307
16	Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. Journal of Neurology, 1999, 246, 477-485.	3.6	298
17	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. Alzheimer's and Dementia, 2019, 15, 888-898.	0.8	290
18	Prevalence and prognosis of Alzheimerâ€™s disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	7.6	284

#	Article	IF	Citations
19	Recommendations to standardize preanalytical confounding factors in Alzheimerâ€™s and Parkinsonâ€™s disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430.	1.4	280
20	Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 491-7.	1.9	259
21	The cerebrospinal fluid â€œAlzheimer profileâ€: Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.8	249
22	Epigenetic regulation in the pathophysiology of Alzheimer's disease. Progress in Neurobiology, 2010, 90, 498-510.	5.7	237
23	Subjective cognitive decline and rates of incident Alzheimer's disease and nonâ€“Alzheimer's disease dementia. Alzheimer's and Dementia, 2019, 15, 465-476.	0.8	232
24	Suspected non-Alzheimer disease pathophysiology â€” concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	10.1	230
25	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	2.6	215
26	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	2.4	197
27	Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology, 2006, 67, 1201-1207.	1.1	191
28	Increased risk of mortality associated with social isolation in older men: only when feeling lonely? Results from the Amsterdam Study of the Elderly (AMSTEL). Psychological Medicine, 2012, 42, 843-853.	4.5	186
29	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurology, The, 2017, 16, 965-975.	10.2	175
30	Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 439-442.	1.9	165
31	Cerebrospinal fluid AÎ²42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimer's and Dementia, 2013, 9, 481-487.	0.8	164
32	Predictive Accuracy of MCI Subtypes for Alzheimerâ€™s Disease and Vascular Dementia in Subjects with Mild Cognitive Impairment: A 2-Year Follow-Up Study. Dementia and Geriatric Cognitive Disorders, 2005, 19, 113-119.	1.5	162
33	Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology, 2012, 78, 468-476.	1.1	154
34	Retinal thickness in Alzheimer's disease: A systematic review andÂmetaâ€analysis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 162-170.	2.4	152
35	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	10.1	144
36	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 353-366.	2.3	140

#	Article	IF	Citations
37	Predictive value of APOE-Â4 allele for progression from MCI to AD-type dementia: a meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1149-1156.	1.9	136
38	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.8	134
39	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
40	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
41	Thalamic volume predicts performance on tests of cognitive speed and decreases in healthy aging. Cognitive Brain Research, 2001, 11, 377-385.	3.0	131
42	Biomarkers as Predictors for Conversion from Mild Cognitive Impairment to Alzheimer-Type Dementia: Implications for Trial Design. Journal of Alzheimer's Disease, 2010, 20, 881-891.	2.6	130
43	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology, 2012, 79, 1809-1816.	1.1	129
44	Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review. PLoS ONE, 2015, 10, e0136181.	2.5	129
45	Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimerâ€™s disease. Brain Structure and Function, 2011, 215, 265-271.	2.3	126
46	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-Î² 1â€“42 Analysis Results. Clinical Chemistry, 2018, 64, 576-585.	3.2	126
47	New MRI Markers for Alzheimer's Disease: A Meta-Analysis of Diffusion Tensor Imaging and a Comparison with Medial Temporal Lobe Measurements. Journal of Alzheimer's Disease, 2012, 29, 405-429.	2.6	125
48	The relation between global and limbic brain volumes on MRI and cognitive performance in healthy individuals across the age range. Neurobiology of Aging, 2000, 21, 569-576.	3.1	123
49	Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology, 2013, 81, 1409-1416.	1.1	122
50	Hippocampal volume change measurement: Quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST. NeuroImage, 2014, 92, 169-181.	4.2	117
51	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.8	113
52	Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology, 2013, 80, 1124-1132.	1.1	110
53	Distinction Between Preclinical Alzheimer's Disease and Depression. Journal of the American Geriatrics Society, 2000, 48, 479-484.	2.6	108
54	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.8	108

#	Article	IF	Citations
55	Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1348-1354.	1.9	107
56	Atrophy subtypes in prodromal Alzheimerâ€™s disease are associated with cognitive decline. Brain, 2018, 141, 3443-3456.	7.6	102
57	Cortical sources of resting EEG rhythms in mild cognitive impairment and subjective memory complaint. Neurobiology of Aging, 2010, 31, 1787-1798.	3.1	97
58	ATN classification and clinical progression in subjective cognitive decline. Neurology, 2020, 95, e46-e58.	1.1	97
59	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
60	Modifiable Risk Factors for Prevention ofÂDementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index. Journal of Alzheimer's Disease, 2017, 58, 537-547.	2.6	95
61	Optical coherence tomography angiography in preclinical Alzheimerâ€™s disease. British Journal of Ophthalmology, 2020, 104, 157-161.	3.9	95
62	Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychological Medicine, 2013, 43, 911-920.	4.5	93
63	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.8	90
64	Pathophysiological subtypes of Alzheimerâ€™s disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	7.6	89
65	Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimerâ€™s Disease. Neuroepidemiology, 2008, 30, 254-265.	2.3	86
66	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. Neurobiology of Aging, 2013, 34, 2003-2013.	3.1	86
67	Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. NeuroImage, 2016, 124, 442-454.	4.2	85
68	Age dependency of risk factors for cognitive decline. BMC Geriatrics, 2018, 18, 187.	2.7	85
69	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	10.2	85
70	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.8	82
71	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging, 2016, 44, 1-8.	3.1	80
72	36â€month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 29-40.	0.8	77

#	Article	IF	Citations
73	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiology of Aging, 2012, 33, 2272-2281.	3.1	75
74	Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 319-327.	2.6	73
75	Variability of CSF Alzheimerâ€™s Disease Biomarkers: Implications for Clinical Practice. PLoS ONE, 2014, 9, e100784.	2.5	72
76	Brain correlates of memory dysfunction in alcoholic Korsakoff's syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 774-778.	1.9	71
77	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medicalâ€‰Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	3.7	70
78	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. Alzheimer's Research and Therapy, 2017, 9, 27.	6.2	66
79	Predictive Value of Mild Cognitive Impairment for Dementia. Dementia and Geriatric Cognitive Disorders, 2009, 27, 173-181.	1.5	65
80	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a â€˜European <scp>ADNI</scp> studyâ€™. Journal of Internal Medicine, 2016, 279, 576-591.	6.0	64
81	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	6.2	64
82	Heritability estimates for 361 blood metabolites across 40 genome-wide association studies. Nature Communications, 2020, 11, 39.	12.8	64
83	Characteristics of helpâ€seeking behaviour in subjects with subjective memory complaints at a memory clinic: a caseâ€control study. International Journal of Geriatric Psychiatry, 2009, 24, 190-196.	2.7	63
84	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	6.2	62
85	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.8	62
86	Affective symptoms as predictors of Alzheimer's disease in subjects with mild cognitive impairment: a 10-year follow-up study. Psychological Medicine, 2010, 40, 1193-1201.	4.5	61
87	Genetic Loci Associated with Alzheimerâ€™s Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort. PLoS ONE, 2013, 8, e59676.	2.5	61
88	Unbiased estimates of cerebrospinal fluid Î²-amyloid 1â€“42 cutoffs in a large memory clinic population. Alzheimer's Research and Therapy, 2017, 9, 8.	6.2	60
89	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 167-182.e1.	3.1	60
90	Do Instrumental Activities of Daily Living Predict Dementia at 1â€•and 2â€Year Followâ€Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia<scp>A</scp>lzheimer's Disease Study. Journal of the American Geriatrics Society, 2011, 59, 2273-2281.	2.6	59

#	Article	IF	Citations
91	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiology of Aging, 2017, 53, 1-10.	3.1	59
92	The Association between APOE Genotype and Memory Dysfunction in Subjects with Mild Cognitive Impairment Is Related to Age and Alzheimer Pathology. Dementia and Geriatric Cognitive Disorders, 2008, 26, 101-108.	1.5	58
93	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
94	Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 26-35.	2.4	58
95	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
96	Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 511-522.	0.8	55
97	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.1	55
98	Brain SPECT in subtypes of mild cognitive impairment. Journal of Neurology, 2008, 255, 1344-1353.	3.6	54
99	Use of amyloid-PET to determine cutpoints for CSF markers. Neurology, 2016, 86, 50-58.	1.1	54
100	Amyloid-Î² Oligomers Relate to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 35-43.	2.6	52
101	Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects. Journal of Neurology, 2002, 249, 312-319.	3.6	51
102	The ICTUS Study: A Prospective Longitudinal Observational Study of 1,380 AD Patients in Europe. Neuroepidemiology, 2007, 29, 29-38.	2.3	51
103	Gray matter network disruptions and amyloid beta in cognitively normal adults. Neurobiology of Aging, 2016, 37, 154-160.	3.1	51
104	Mild cognitive impairment as predictor for Alzheimer's disease in clinical practice: effect of age and diagnostic criteria. Psychological Medicine, 2008, 38, 113-122.	4.5	50
105	The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiology of Aging, 2012, 33, 201.e1-201.e8.	3.1	48
106	The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimer's Research and Therapy, 2018, 10, 75.	6.2	48
107	Biomarker profiles and their relation to clinical variables in mild cognitive impairment. Neurocase, 2005, 11, 8-13.	0.6	47
108	Symptoms of Preclinical Dementia in General Practice up to Five Years before Dementia Diagnosis. Dementia and Geriatric Cognitive Disorders, 2007, 24, 300-306.	1.5	47

#	Article	IF	Citations
109	Comparison of International Working Group criteria and National Institute on Agingâ€“Alzheimer's Association criteria for Alzheimer'sÂdisease. Alzheimer's and Dementia, 2012, 8, 560-563.	0.8	47
110	Assessing Amyloid Pathology in Cognitively Normal Subjects Using ¹⁸F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. Journal of Nuclear Medicine, 2019, 60, 541-547.	5.0	47
111	Secondary prevention of Alzheimerâ€™s dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	6.2	46
112	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.8	46
113	Course of objective memory impairment in non-demented subjects attending a memory clinic and predictors of outcome. International Journal of Geriatric Psychiatry, 2000, 15, 363-372.	2.7	45
114	Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 1149-1159.	0.8	45
115	The Dementias Platform UK (DPUK) Data Portal. European Journal of Epidemiology, 2020, 35, 601-611.	5.7	45
116	Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. Alzheimer's and Dementia, 2018, 14, 130-139.	0.8	44
117	Time from diagnosis to institutionalization and death in people with dementia. Alzheimer's and Dementia, 2020, 16, 662-671.	0.8	44
118	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimer's and Dementia, 2021, 17, 1189-1204.	0.8	44
119	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research and Therapy, 2017, 9, 101.	6.2	43
120	SPECT Predictors of Cognitive Decline and Alzheimer's Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2009, 17, 761-772.	2.6	42
121	Genome-wide association study of Alzheimerâ€™s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	4.8	42
122	Single-Domain Amnestic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study. Dementia and Geriatric Cognitive Disorders, 2013, 36, 1-19.	1.5	41
123	Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimerâ€™s disease: A literature review. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 86-98.	6.1	40
124	Spatial-Temporal Patterns of Î²-Amyloid Accumulation. Neurology, 2022, 98, .	1.1	40
125	White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1069-1074.	1.9	39
126	The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. Psychological Medicine, 2015, 45, 1509-1519.	4.5	39

#	Article	IF	Citations
127	Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. Human Brain Mapping, 2016, 37, 2114-2132.	3.6	38
128	Functional and effective whole brain connectivity using magnetoencephalography to identify monozygotic twin pairs. Scientific Reports, 2017, 7, 9685.	3.3	38
129	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. NeuroImage, 2020, 218, 116932.	4.2	38
130	Impact of APOE-É›4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. Neurobiology of Aging, 2016, 38, 14-20.	3.1	37
131	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. Neurology, 2021, 96, e2673-e2684.	1.1	37
132	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	2.4	36
133	Retinal layer thickness in preclinical Alzheimer's disease. Acta Ophthalmologica, 2019, 97, 798-804.	1.1	36
134	Differential insular cortex sub-regional atrophy in neurodegenerative diseases: a systematic review and meta-analysis. Brain Imaging and Behavior, 2020, 14, 2799-2816.	2.1	36
135	Normal Cognitive Performance in Patients With Chronic Alcoholism in Contrast to Patients With Korsakoff's Syndrome. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 44-50.	1.8	34
136	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite ‹scp›E‹/scp›uropean 3T study on healthy elderly. Human Brain Mapping, 2015, 36, 3516-3527.	3.6	34
137	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimerâ€™s Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	2.6	34
138	Relation of Odor Identification with Alzheimerâ€™s Disease Markers in Cerebrospinal Fluid and Cognition. Journal of Alzheimer's Disease, 2017, 60, 1025-1034.	2.6	33
139	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's and Dementia, 2017, 13, 903-912.	0.8	32
140	Age and the association of dementia-related pathology with trajectories of cognitive decline. Neurobiology of Aging, 2018, 61, 138-145.	3.1	32
141	Diagnosis of Preclinical Alzheimer's Disease in a Clinical Setting. International Psychogeriatrics, 2001, 13, 411-423.	1.0	31
142	Consensus statement on dementia education and training in Europe. Journal of Nutrition, Health and Aging, 2010, 14, 131-135.	3.3	31
143	Generalizability of the Disease State Index Prediction Model for Identifying Patients Progressing from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 79-92.	2.6	31
144	Cost-Utility of Using Alzheimerâ€™s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. Journal of Alzheimer's Disease, 2017, 60, 1477-1487.	2.6	31

#	Article	IF	Citations
145	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, 27.	10.8	30
146	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Frontiers in Aging Neuroscience, 2018, 10, 67.	3.4	29
147	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.8	29
148	Medial Temporal Lobe Atrophy and APOE Genotype Do Not Predict Cognitive Improvement upon Treatment with Rivastigmine in Alzheimerâ€™s Disease Patients. Dementia and Geriatric Cognitive Disorders, 2005, 19, 126-133.	1.5	28
149	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 2018, 10, 409.	3.4	28
150	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. Alzheimer's Research and Therapy, 2019, 11, 74.	6.2	28
151	White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study. Journal of the American Geriatrics Society, 2019, 67, 1827-1834.	2.6	28
152	APOE Îµ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 65.	6.2	28
153	Remote monitoring technologies in Alzheimerâ€™s disease: design of the RADAR-AD study. Alzheimer's Research and Therapy, 2021, 13, 89.	6.2	28
154	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	3.1	27
155	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	3.1	27
156	Memory Correlates of Alzheimerâ€™s Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1119-1128.	2.6	27
157	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101786.	2.7	27
158	A framework for assessing neuropsychiatric phenotypes by using smartphone-based location data. Translational Psychiatry, 2020, 10, 211.	4.8	27
159	Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. Scientific Reports, 2021, 11, 22675.	3.3	27
160	Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned?. Alzheimer's and Dementia, 2006, 2, 220-233.	0.8	25
161	Relationship between genetic risk factors and markers for Alzheimerâ€™s disease pathology. Biomarkers in Medicine, 2012, 6, 477-495.	1.4	25
162	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimer's Research and Therapy, 2017, 9, 73.	6.2	25

#	Article	IF	Citations
163	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatrics, 2018, 18, 289.	2.7	25
164	Retinal thickness as a potential biomarker in patients with amyloidâ€proven earlyâ€•and lateâ€onset Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 463-471.	2.4	25
165	Diagnostic and economic evaluation of new biomarkers for Alzheimerâ€™s disease: the research protocol of a prospective cohort study. BMC Neurology, 2012, 12, 72.	1.8	24
166	Association Between Later Life Lifestyle Factors and Alzheimerâ€™s Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1387-1395.	2.6	24
167	Challenges for Optimizing Real-World Evidence in Alzheimerâ€™s Disease: The ROADMAP Project. Journal of Alzheimer's Disease, 2019, 67, 495-501.	2.6	24
168	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. Magnetic Resonance Imaging, 2021, 76, 108-115.	1.8	24
169	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.8	24
170	DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. Epigenomics, 2015, 7, 533-537.	2.1	23
171	Preâ€amyloid stage of Alzheimer's disease in cognitively normal individuals. Annals of Clinical and Translational Neurology, 2018, 5, 1037-1047.	3.7	23
172	Plasma Aβ42 as a Biomarker of Prodromal Alzheimerâ€™s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. Journal of Alzheimer's Disease, 2019, 69, 37-48.	2.6	23
173	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.8	23
174	Predicting Progression from Cognitive Impairment to Alzheimerâ€™s Disease with the Disease State Index. Current Alzheimer Research, 2015, 12, 69-79.	1.4	22
175	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.8	22
176	Progression to dementia in memory clinic patients without dementia. Neurology, 2013, 81, 1342-1349.	1.1	21
177	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. Journal of Psychiatric Research, 2018, 104, 183-191.	3.1	21
178	The Diagnostic and Prognostic Value ofÂNeuropsychological Assessment inÂMemory Clinic Patients. Journal of Alzheimer's Disease, 2016, 55, 679-689.	2.6	20
179	Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease. Psychiatry Research - Neuroimaging, 2016, 252, 26-35.	1.8	20
180	Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects. Annals of Neurology, 2017, 81, 749-753.	5.3	20

#	Article	IF	Citations
181	White matter hyperintensities and vascular risk factors in monozygotic twins. Neurobiology of Aging, 2018, 66, 40-48.	3.1	20
182	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimer's and Dementia, 2018, 14, 837-842.	0.8	20
183	The MOPEAD project: Advancing patient engagement for the detection of â€œhiddenâ€•undiagnosed cases of Alzheimer's disease in the community. , 2019, 15, 828-839.		20
184	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimer's Research and Therapy, 2019, 11, 94.	6.2	20
185	The European medical information framework: A novel ecosystem for sharing healthcare data across Europe. Learning Health Systems, 2020, 4, e10214.	2.0	20
186	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. Annals of Neurology, 2021, 89, 987-1000.	5.3	20
187	MCI is not a clinically useful concept. International Psychogeriatrics, 2006, 18, 402-9; discussion 409-14.	1.0	20
188	Genome-Wide Association Study of Alzheimerâ€™s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimerâ€™s Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	3.4	20
189	Can novel therapeutics halt the amyloid cascade?. Alzheimer's Research and Therapy, 2010, 2, 5.	6.2	19
190	Disclosure of Alzheimerâ€™s disease biomarker status in subjects with mild cognitive impairment. Biomarkers in Medicine, 2012, 6, 365-368.	1.4	19
191	The association of vascular disorders with incident dementia in different age groups. Alzheimer's Research and Therapy, 2019, 11, 47.	6.2	19
192	Plasma amyloid-Î² oligomerization assay as a pre-screening test for amyloid status. Alzheimer's Research and Therapy, 2021, 13, 133.	6.2	19
193	Regional Differences in Effects of <i>APOE</i> Îµ4 on Cognitive Impairment in Non-Demented Subjects. Dementia and Geriatric Cognitive Disorders, 2011, 32, 135-142.	1.5	18
194	Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimerâ€™s Disease: Structural Brain Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 3-14.	2.6	18
195	Four subgroups based on tau levels in Alzheimerâ€™s disease observed in two independent cohorts. Alzheimer's Research and Therapy, 2021, 13, 2.	6.2	18
196	The Effect of Psychological Distress and Personality Traits on Cognitive Performances and the Risk of Dementia in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 46, 805-812.	2.6	17
197	The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 513-523.	3.7	17
198	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. Alzheimer's and Dementia, 2014, 10, 456-467.	0.8	16

#	Article	IF	Citations
199	Genetic Risk as a Marker of Amyloid-Î² and Tau Burden in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2016, 55, 1417-1427.	2.6	16
200	Amyloid-Î², Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. Frontiers in Aging Neuroscience, 2018, 10, 193.	3.4	16
201	White matter microstructure disruption in early stage amyloid pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12124.	2.4	16
202	Plasma Proteomic Biomarkers Relating to Alzheimerâ€™s Disease: A Meta-Analysis Based on Our Own Studies. Frontiers in Aging Neuroscience, 2021, 13, 712545.	3.4	16
203	Course of minimal dementia and predictors of outcome. International Journal of Geriatric Psychiatry, 2002, 17, 835-841.	2.7	15
204	Boosting translational research on Alzheimer's disease in Europe: The Innovative Medicine Initiative AD research platform. Alzheimer's and Dementia, 2015, 11, 1121-1122.	0.8	15
205	Brain Amyloid Pathology and Cognitive Function. JAMA - Journal of the American Medical Association, 2017, 317, 2285.	7.4	15
206	Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions. , 2018, 59, 5025.		15
207	The Effect of the APOE-ε4 Allele and ACE-I/D Polymorphism on Cognition during a Two-Year Follow-Up in First-Ever Stroke Patients. Dementia and Geriatric Cognitive Disorders, 2010, 29, 534-542.	1.5	14
208	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. Neurobiology of Aging, 2019, 77, 58-65.	3.1	14
209	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 1-9.	2.4	14
210	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021, 76, 1499-1511.	3.9	14
211	Decline in cognitively complex everyday activities accelerates along the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2020, 12, 138.	6.2	14
212	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. Brain Communications, 2021, 3, fcab201.	3.3	14
213	Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI. Neurology, 2009, 73, 744-745.	1.1	13
214	Realâ€world evidence in Alzheimer's disease: The ROADMAP Data Cube. Alzheimer's and Dementia, 2020, 16, 461-471.	0.8	13
215	Longitudinal retinal layer changes in preclinical Alzheimerâ€™s disease. Acta Ophthalmologica, 2021, 99, 538-544.	1.1	13
216	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimerâ€™s Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	2.6	13

#	Article	IF	Citations
217	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2020, 76, 1061-1070.	2.6	13
218	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.8	13
219	Early-Onset Dementia. Alzheimer Disease and Associated Disorders, 2017, 31, 146-151.	1.3	12
220	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research and Therapy, 2020, 12, 8.	6.2	12
221	Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase caseâ€“control study using European electronic health records. BMJ Open, 2020, 10, e038753.	1.9	12
222	Insights into the changes in the proteome of Alzheimer disease elucidated by a meta-analysis. Scientific Data, 2021, 8, 312.	5.3	12
223	Genetically identical twins show comparable tau PET load and spatial distribution. Brain, 2022, 145, 3571-3581.	7.6	12
224	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. Journal of Alzheimer's Disease, 2017, 60, 201-210.	2.6	11
225	CSF cutoffs for MCI due to AD depend on APOEÎµ4 carrier status. Neurobiology of Aging, 2020, 89, 55-62.	3.1	11
226	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimerâ€™s disease. Brain Communications, 2020, 2, fcaa102.	3.3	11
227	The Predictive Value of Memory Strategies for Alzheimer's Disease in Subjects with Mild Cognitive Impairment. Archives of Clinical Neuropsychology, 2010, 25, 71-77.	0.5	10
228	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimerâ€™s Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	2.6	10
229	Cognitive functioning of individuals aged 90 years and older without dementia: A systematic review. Ageing Research Reviews, 2017, 36, 42-49.	10.9	10
230	Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology, 2019, 92, e2699-e2705.	1.1	10
231	General practitionersâ€™ attitude toward early and preâ€dementia diagnosis of AD in five European countriesâ€”A MOPEAD project survey. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12130.	2.4	10
232	ALZHEIMERâ€™S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMERâ€™S DISEASE. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-5.	2.7	10
233	Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimerâ€™s disease biomarkers. Clinical Proteomics, 2022, 19, 13.	2.1	10
234	Amyloidâ€Î², cortical thickness, and subsequent cognitive decline in cognitively normal oldestâ€old. Annals of Clinical and Translational Neurology, 2021, 8, 348-358.	3.7	9

#	Article	IF	Citations
235	CSF Proteomic Alzheimerâ€™s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	3.5	9
236	A methodology for cohort harmonisation in multicentre clinical research. Informatics in Medicine Unlocked, 2021, 27, 100760.	3.4	9
237	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimerâ€™s disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	7.9	9
238	Regional associations of white matter hyperintensities and early cortical amyloid pathology. Brain Communications, 2022, 4, .	3.3	9
239	Characteristics of preclinical Alzheimer's disease. International Journal of Geriatric Psychiatry, 2002, 17, 88-89.	2.7	8
240	CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer's Disease Consortium (EADC). Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 124-125.	1.9	8
241	Biomarkers for Alzheimer's disease: a controversial topic. Lancet Neurology, The, 2015, 14, 781-783.	10.2	8
242	Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort. Journal of Alzheimer's Disease, 2016, 52, 875-885.	2.6	8
243	Preclinical Alzheimerâ€™s Disease: Implications for Refinement of the Concept. Journal of Alzheimer's Disease, 2018, 64, S213-S227.	2.6	8
244	Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 69, 49-58.	2.6	8
245	Ocular biomarkers for cognitive impairment in nonagenarians; a prospective cross-sectional study. BMC Geriatrics, 2020, 20, 155.	2.7	8
246	Duration of Care Trajectories in Persons With Dementia Differs According to Demographic and Clinical Characteristics. Journal of the American Medical Directors Association, 2020, 21, 1102-1107.e6.	2.5	8
247	Identification of undiagnosed dementia cases using a webâ€based preâ€screening tool: The MOPEAD project. Alzheimer's and Dementia, 2021, 17, 1307-1316.	0.8	8
248	Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimerâ€™s disease. World Journal of Biological Psychiatry, 2022, 23, 264-277.	2.6	8
249	Role of cognitive testing in disease modifying AD trials. Journal of Nutrition, Health and Aging, 2006, 10, 131-2; discussion 132-3.	3.3	8
250	Increased CSF-decorin predicts brain pathological changes driven by Alzheimerâ€™s AÎ² amyloidosis. Acta Neuropathologica Communications, 2022, 10, .	5.2	8
251	The Association Between APOE Îµ4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of Alzheimer's Disease, 2013, 35, 241-246.	2.6	7
252	Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60â€“102 Years. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1609-1617.	3.6	7

#	Article	IF	Citations
253	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	2.6	7
254	Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. Neurobiology of Aging, 2020, 93, 144.e1-144.e15.	3.1	7
255	Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12216.	2.4	7
256	Sex-Specific Metabolic Pathways Were Associated with Alzheimerâ€™s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
257	Phenomenology of Depression in Dementia. International Psychogeriatrics, 2000, 12, 129-134.	1.0	6
258	Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Riskâ€”Reply. JAMA - Journal of the American Medical Association, 2015, 314, 1177.	7.4	6
259	Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 256-264.	2.3	6
260	Research diagnostic criteria for Alzheimerâ€™s disease: findings from the LipiDiDiet randomized controlled trial. Alzheimer's Research and Therapy, 2021, 13, 64.	6.2	6
261	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. Translational Psychiatry, 2021, 11, 451.	4.8	6
262	MILD COGNITIVE IMPAIRMENT SUBTYPES AND VASCULAR DEMENTIA. Journal of the American Geriatrics Society, 2006, 54, 1966-1967.	2.6	5
263	Genetic overlap between Alzheimer's disease and blood lipid levels. Neurobiology of Aging, 2021, 108, 189-195.	3.1	5
264	Magnetoencephalography Brain Signatures Relate to Cognition and Cognitive Reserve in the Oldest-Old: The EMIF-AD 90 + Study. Frontiers in Aging Neuroscience, 2021, 13, 746373.	3.4	5
265	P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. Alzheimer's Research and Therapy, 2022, 14, .	6.2	5
266	Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment. Journal of Nutrition, Health and Aging, 2009, 13, 344-345.	3.3	4
267	APOE -Îµ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a community setting. The Cochrane Library, 0, , .	2.8	4
268	APOE -Îµ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a primary care setting. The Cochrane Library, 0, , .	2.8	4
269	APOE-Îµ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a secondary care setting. The Cochrane Library, 0, , .	2.8	4
270	[P4â€“157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUTâ€OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1319.	0.8	4

#	Article	IF	Citations
271	[O2â€“12â€“03]: DURATION OF ALZHEIMER's DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAGE: A MULTIâ€STATE MODEL ANALYSIS. Alzheimer's and Dementia, 2017, 13, P585.	0.8	4
272	Capturing the Alzheimer's disease pathological cascade. Lancet Neurology, The, 2018, 17, 199-200.	10.2	4
273	A Cost-Consequence Analysis of Different Screening Procedures in Alzheimerâ€™s Disease: Results from the MOPEAD Project. Journal of Alzheimer's Disease, 2021, 83, 1149-1159.	2.6	4
274	Effects of age, amyloid, sex, and APOE Îµ4 on the CSF proteome in normal cognition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12286.	2.4	4
275	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.8	4
276	Magnesium therapy in acute myocardial infarction. Netherlands Journal of Medicine, 1995, 46, 156-165.	0.5	3
277	P4â€224: Alzheimerâ€™s Disease Patients With Osas History Have Higher CSF Tau Levels. Alzheimer's and Dementia, 2016, 12, P1115.	0.8	3
278	Microvascular changes of the retina in ankylosing spondylitis, and the association with cardiovascular disease â€“ the eye for a heart study. Seminars in Arthritis and Rheumatism, 2020, 50, 1535-1541.	3.4	3
279	Complementary preâ€screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project. Alzheimer's and Dementia, 2021, , .	0.8	3
280	MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study. Current Alzheimer Research, 2016, 13, 1407-1413.	1.4	3
281	CSF proteomic signature predicts progression to Alzheimer's disease dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12240.	3.7	3
282	Evaluating robustness of the Centiloid scale against variations in amyloid PET image resolution. Alzheimer's and Dementia, 2021, 17, .	0.8	3
283	P2-274: Risk score profiles for prediction of dementia in the general elderly population. , 2015, 11, P596-P596.		2
284	P2-188: Characterization of cognitive function with the cantab in individuals with amnestic mild cognitive impairment in relation to hippocampal volume, amyloid, and tau status: Preliminary baseline results from the PharmaCog/european-ADNI study. , 2015, 11, P564-P564.		2
285	O3-05-03: Modifiable Risk Factors for Prevention of Dementia in Midlife and Late Life: The Libra Index. , 2016, 12, P295-P296.		2
286	ICâ€Pâ€120: Association Between Brain MRI Diffusion Alterations and CSF Biomarkers in Amnestic MCI. Alzheimer's and Dementia, 2016, 12, P89.	0.8	2
287	DTâ€01â€04: Effects of Fortasyn Connect (Souvenaid) on Longitudinal Brain Atrophy Measures in Prodromal Alzheimerâ€™s Disease: Results of the Doubleâ€Blind Randomised Controlled Lipididiet Trial. Alzheimer's and Dementia, 2016, 12, P1135.	0.8	2
288	ICâ€Pâ€039: Impairment of Restingâ€State Functional Connectivity in The Defaultâ€Mode Network Closely Tracks CSF Biomarkers In MCI. Alzheimer's and Dementia, 2016, 12, P34.	0.8	2

#	Article	IF	Citations
289	Chasing the start of sporadic Alzheimerâ€™s disease running in families. Brain, 2018, 141, 1589-1591.	7.6	2
290	Pathophysiological subtypes of Alzheimerâ€™s disease based on cerebrospinal fluid proteomics. Alzheimer's and Dementia, 2020, 16, e037184.	0.8	2
291	Proteomic correlates of cortical thickness in cognitively normal individuals with normal and abnormal cerebrospinal fluid beta-amyloid1-42. Neurobiology of Aging, 2021, 107, 42-52.	3.1	2
292	Assessment of Social Behavior Using a Passive Monitoring App in Cognitively Normal and Cognitively Impaired Older Adults: Observational Study. JMIR Aging, 2022, 5, e33856.	3.0	2
293	An app to measure functional decline in managing finances in Alzheimerâ€™s disease: Preliminary results of the RADARâ€AD study. Alzheimer's and Dementia, 2021, 17, .	0.8	2
294	Dataâ€driven evidence for three distinct patterns of amyloidâ€Î²2 accumulation. Alzheimer's and Dementia, 2021, 17, .	0.8	2
295	Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology, 2007, 68, 1238-1239.	1.1	1
296	Fluid biomarkers for Alzheimerâ€™s disease: standardization and recent developments. Biomarkers in Medicine, 2012, 6, 363-364.	1.4	1
297	O3-08-01: The prevalence of amyloid pathology in healthy individuals and individuals with mild cognitive impairment: A meta-analysis of amyloid-PET studies. , 2013, 9, P533-P533.		1
298	FTS-01-01: A european medical information framework for Alzheimer's disease (EMIF-AD). , 2015, 11, P120-P121.		1
299	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
300	P3â€315: Differential Effects of Apoe and CSF Amyloid on Memory Impairment in Individuals with Amnestic MCI Using the Cantab Cognitive Battery: Results from the Europeanâ€Adni Study. Alzheimer's and Dementia, 2016, 12, P964.	0.8	1
301	P4â€153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Nonâ€AD in Memory Clinic and Communityâ€Based Cohorts. Alzheimer's and Dementia, 2016, 12, P1073.	0.8	1
302	[P2â€“212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIFâ€AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.	0.8	1
303	P4â€158: THE ASSOCIATION OF VASCULAR DISORDERS WITH INCIDENT DEMENTIA AND MORTALITY IN DIFFERENT AGE GROUPS IN A PRIMARY CARE DATABASE. Alzheimer's and Dementia, 2018, 14, P1499.	0.8	1
304	ICâ€Pâ€182: EVENTâ€BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL Î²â€AMYLOID DEPOSITION IN THE BRAIN. Alzheimer's and Dementia, 2018, 14, P152.	0.8	1
305	ICâ€Pâ€126: VOLUMETRIC ACCURACY OF A FULLY AUTOMATIC TOOL FOR WHITE MATTER HYPERINTENSITIES (WMHS) SEGMENTATION. Alzheimer's and Dementia, 2018, 14, P105.	0.8	1
306	P2â€445: EVENTâ€BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL Î²â€AMYLOID DEPOSITION IN THE BRAIN. Alzheimer's and Dementia, 2018, 14, P887.	0.8	1

#	Article	IF	Citations
307	P1â€247: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AS A DIFFERENTIAL DIAGNOSIS BIOMARKER IN NEUROLOGICAL DISEASES: A SYSTEMATIC REVIEW AND METAANALYSIS. Alzheimer's and Dementia, 2018, 14, P373.	0.8	1
308	Predictors of preclinical Alzheimerâ€™s disease in persons with subjective cognitive decline. Alzheimer's and Dementia, 2020, 16, e042658.	0.8	1
309	The IMIâ€EU H2020 project MOPEAD: Outcome of different screening methods to identify MCI/early AD. Alzheimer's and Dementia, 2020, 16, e044524.	0.8	1
310	Trajectories of decline in cognitively complex everyday activities across the Alzheimerâ€™s disease continuum. Alzheimer's and Dementia, 2020, 16, e044787.	0.8	1
311	Preâ€screening models for patient engagement: The MOPEAD project. Alzheimer's and Dementia, 2020, 16, e044796.	0.8	1
312	Cerebrospinal fluid proteomic profiles predict progression to dementia in prodromal AD. Alzheimer's and Dementia, 2020, 16, e045230.	0.8	1
313	Social behavior assessment in cognitively impaired older adults using a passive and remote smartphone application. Alzheimer's and Dementia, 2021, 17, e051698.	0.8	1
314	Updated prevalence estimates of amyloid positivity from cognitively normal to clinical Alzheimerâ€™s disease dementia: The Amyloid Biomarker Study. Alzheimer's and Dementia, 2021, 17, .	0.8	1
315	Augmented reality to detect subtle alterations in the early stages of Alzheimerâ€™s disease: Preliminary results of the RADARâ€AD study. Alzheimer's and Dementia, 2021, 17, .	0.8	1
316	Gait characteristics in preclinical Alzheimerâ€™s disease: Preliminary results of the RADARâ€AD study. Alzheimer's and Dementia, 2021, 17, .	0.8	1
317	S1-02-02: Clinical and neuropsychological features as predictors from MCI to Alzheimer's-type dementia. , 2013, 9, P122-P122.		0
318	IC-P-224: THE HIPPOCAMPAL BOUNDARY SHIFT INTEGRAL IS 70% MORE REPRODUCIBLE THAN OTHER ATROPHY ALGORITHMS. , 2014, 10, P120-P121.		0
319	O2-05-03: USE OF CSF AMYLOID FOR DETECTING CORTICAL AMYLOID DEPOSITION: A MULTICENTER STUDY. , 2014, 10, P173-P173.		0
320	P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly. , 2015, 11, P689-P689.		0
321	P4-040: Use of recent research criteria for inclusion and use of biomarkers as endpoint in preclinical and prodromal Alzheimer's disease (AD) trials: An Alzheimer's disease neuroimaging initiative (ADNI) study. , 2015, 11, P780-P781.		0
322	O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF). , 2015, 11, P130-P130.		0
323	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test. , 2015, 11, P272-P272.		0
324	IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly. , 2015, 11, P11-P11.		0

#	Article	IF	Citations
325	O1-03-06: Creating normative values for cognitive tests in amyloid positive and amyloid negative cognitively normal subjects. , 2015, 11, P131-P132.		0
326	IC-P-108: Impact of ApoE-Æ4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. , 2015, 11, P73-P73.		0
327	P1-011: Prevalence of amyloid and neurodegeneration markers and effects on cognitive functioning in non-demented subjects. , 2015, 11, P340-P341.		0
328	O2-09-01: Impact of ApoE-É›4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. , 2015, 11, P194-P194.		0
329	F3-02-03: Prevalence of snap in subjects with mild cognitive impairment and dementia. , 2015, 11, P213-P214.		0
330	O3-11-02: Prevalence and diagnostic procedures in early-onset dementia in tertiary referral center patients in denmark, sweden, and the netherlands. , 2015, 11, P244-P245.		0
331	F4-02-02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors. , 2015, 11, P260-P261.		0
332	P3-031: EPAD Register: A Novel Tool for Pre-Screening Participants in the IMI European Prevention of Alzheimerâ€™s Dementia Project (EPAD). , 2016, 12, P828-P829.		0
333	P4â€122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimerâ€™s Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.8	0
334	ICâ€Pâ€017: Concordance of [18F]Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P23.	0.8	0
335	IC-02-04: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P7-P8.		0
336	P1â€264: Structural and Diffusion Tensor Imaging in MCI Subjects With Intermediate Risk of Alzheimerâ€™s Disease Based on CSF Profile. Alzheimer's and Dementia, 2016, 12, P514.	0.8	0
337	P1-366: Subjective Versus Objective Cognitive Decline in Memory Clinic Visitors. , 2016, 12, P571-P571.		0
338	P2-165: Resilience to Clinical Dementia at Old Age: The European Medical Information Framework (EMIF) 90+ Study. , 2016, 12, P678-P678.		0
339	P2-237: Concordance of [18F] Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P714-P715.		0
340	ICâ€Pâ€122: Structural and Diffusion Tensor Imaging in MCI Subjects With Intermediate Risk of Alzheimerâ€™s Disease Based on CSF Profile. Alzheimer's and Dementia, 2016, 12, P90.	0.8	0
341	ICâ€Pâ€147: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P109.	0.8	0
342	ICâ€Pâ€148: Association Between Volumes Alterations and CSF Biomarkers in Amnestic MCI. Alzheimer's and Dementia, 2016, 12, P110.	0.8	0

#	Article	IF	Citations
343	P3â€232: Association Between Brain MRI Diffusion Alterations and CSF Biomarkers in Amnestic MCI. Alzheimer's and Dementia, 2016, 12, P914.	0.8	0
344	P3â€269: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P935.	0.8	0
345	P4â€112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Nonâ€Demented Elderly. Alzheimer's and Dementia, 2016, 12, P1055.	0.8	0
346	P4â€146: Largeâ€Vessel Disease and [18F]Flutemetamolâ€Amyloid Deposition in Cognitively Healthy Elderly Twins. Alzheimer's and Dementia, 2016, 12, P1069.	0.8	0
347	P4-165: Association Between Volume Alterations and CSF Biomarkers in Amnestic MCI. , 2016, 12, P1080-P1080.		0
348	O1-11-03: Prevalence of Amyloid-b Pathology in Primary Progressive Aphasia Variants: A Multicenter Study. , 2016, 12, P202-P203.		0
349	O2â€04â€01: Cognitive Composite Measures in Amnestic MCI by Different AMYLOID/TAU Pathology. Alzheimer's and Dementia, 2016, 12, P229.	0.8	0
350	O2â€05â€02: Dementia Prevalence and Incidence in a Combination of European Electronic Health Records Databases: the EMIFâ€ad EHR Resource. Alzheimer's and Dementia, 2016, 12, P232.	0.8	0
351	O3â€05â€02: Relation Between Lifestyle Factors and Alzheimer's Disease Biomarkers in Subjects with SCI or MCI. Alzheimer's and Dementia, 2016, 12, P294.	0.8	0
352	O3-09-02: Cognitive Consequences of Cerebral Amyloid Pathology in Persons without Dementia. , 2016, 12, P307-P308.		0
353	O4â€02â€04: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P335.	0.8	0
354	P1â€238: When Less is More: Detecting Functional Decline Using a Short Version of the Amsterdam Iadl Questionnaire. Alzheimer's and Dementia, 2016, 12, P498.	0.8	0
355	P4â€350: Biomarkers of Short Term Disease Progression in Mild Cognitive Impairment Patients with ad Pathology. Alzheimer's and Dementia, 2016, 12, P1171.	0.8	0
356	O4â€09â€05: Risk Factors for Cognitive Decline are Age Dependent. Alzheimer's and Dementia, 2016, 12, P356.	0.8	0
357	[P2â€“399]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P783.	0.8	0
358	[P3â€“062]: ACROSSâ€SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTIâ€SITE 3T STUDY. Alzheimer's and Dementia, 2017, 13, P954.	0.8	0
359	[P3â€“214]: ADFLAG^{Â®}, A DIAGNOSTIC BLOOD TEST FOR PREâ€DEMENTIA STAGES OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1019.	0.8	0
360	[P4â€“226]: BEST COMBINATORIAL LOWâ€COST MARKERS TO PREDICT MCI CONVERSION: AN EMIFâ€AD FEDERATION STUDY. Alzheimer's and Dementia, 2017, 13, P1356.	0.8	0

#	Article	IF	Citations
361	[ICâ€Pâ€036]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P32.	0.8	0
362	[ICâ€Pâ€053]: EARLY ALTERATIONS IN RESTINGâ€STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P43.	0.8	0
363	[ICâ€Pâ€058]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P47.	0.8	0
364	[ICâ€Pâ€065]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P53.	0.8	0
365	[ICâ€Pâ€167]: ACROSSâ€SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTIâ€SITE 3T STUDY. Alzheimer's and Dementia, 2017, 13, P126.	0.8	0
366	[P1â€“250]: DECISION TREE ANALYSIS REVEALS TWO CUTâ€OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P342.	0.8	0
367	[P1â€“289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF AÎ² OR AMYLOIDâ€PET) IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361.	0.8	0
368	[P1â€“387]: CHARACTERIZATION OF SUSPECTED NONâ€ALZHEIMER's DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT USING NEUROIMAGING. Alzheimer's and Dementia, 2017, 13, P414.	0.8	0
369	[P1â€“404]: EARLY ALTERATIONS IN RESTINGâ€STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P429.	0.8	0
370	[P1â€“411]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P433.	0.8	0
371	[P1â€“575]: PREVALENCE OF THE APOLIPOPROTEIN E Îµ4 ALLELE IN AMYLOIDâ€Î² POSITIVE SUBJECTS ACROSS THE SPECTRUM OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P515.	0.8	0
372	[F1â€“04â€“02]: EPAD REGISTRY. Alzheimer's and Dementia, 2017, 13, P178.	0.8	0
373	[F1â€“04â€“04]: EUROPEAN MEDICAL FRAMEWORK FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P178.	0.8	0
374	[O1â€“05â€“03]: CSF AMYLOID BETA 1â€“42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSISâ€DEPENDENT UPWARD DRIFT. Alzheimer's and Dementia, 2017, 13, P198.	0.8	0
375	[O2â€“05â€“01]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P559.	0.8	0
376	[O3â€“06â€“03]: THE IMPACT OF AMYLOID AND TAU PATHOLOGY ON THE DEVELOPMENT OF SUBTLE COGNITIVE CHANGES IN PERSONS WITHOUT DEMENTIA. Alzheimer's and Dementia, 2017, 13, P912.	0.8	0
377	[P2â€“194]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NONâ€ALZHEIMER's DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P680.	0.8	0
378	P3â€216: IS THE RELATION BETWEEN BLOOD PRESSURE AND COGNITION DEPENDENT ON AMYLOID PATHOLOGY OR PHYSICAL PERFORMANCE? RESULTS OF THE EMIFâ€AD 90+ STUDY. Alzheimer's and Dementia, 2018, 14, P1153.	0.8	0

#	Article	IF	Citations
379	P3â€368: PREDICTING AND MONITORING SHORTâ€TERM DISEASE PROGRESSION IN Aâ€MCI PATIENTS WITH PRODROMAL AD USING MRI STRUCTURAL BRAIN BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P1230.	0.8	0
380	P2â€270: INCREASED CSF AMYLOIDâ€Î² 1â€38 AND 1â€40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. Alzheimer's and Dementia, 2018, 14, P780.	0.8	0
381	ICâ€Pâ€066: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. Alzheimer's and Dementia, 2018, 14, P59.	0.8	0
382	P3â€233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2018, 14, P1161.	0.8	0
383	O1â€13â€01: ROLE OF THE INFLAMMASOME COMPLEX IN ADâ€RELATED HIPPOCAMPAL NEURODEGENERATION IN MCI PATIENTS WITH AD PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P251.	0.8	0
384	P1â€418: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. Alzheimer's and Dementia, 2018, 14, P465.	0.8	0
385	P1â€525: AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2018, 14, P533.	0.8	0
386	F1â€02â€04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P204.	0.8	0
387	P3â€264: UNBIASED METHOD TO DETERMINE CUTâ€POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION. Alzheimer's and Dementia, 2018, 14, P1176.	0.8	0
388	O2â€09â€06: FREQUENCIES OF CEREBROSPINAL FLUID A/T/N BIOMARKER PROFILES AND THEIR ASSOCIATION WITH MEMORY FUNCTION IN PERSONS WITHOUT DEMENTIA. Alzheimer's and Dementia, 2018, 14, P643.	0.8	0
389	O2â€09â€05: EXTENSION AND VALIDATION OF AN AMYLOID STAGING MODEL: ASSOCIATIONS WITH CLINICAL MEASURES. Alzheimer's and Dementia, 2018, 14, P643.	0.8	0
390	O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. Alzheimer's and Dementia, 2018, 14, P661.	0.8	0
391	O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. Alzheimer's and Dementia, 2018, 14, P1638.	0.8	0
392	ICâ€Pâ€005: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P16.	0.8	0
393	P3â€585: COGNITIVE RESERVE MODULATES THE ASSOCIATION OF CEREBRAL AMYLOID PATHOLOGY WITH COGNITIVE PERFORMANCE IN PERSONS WITH ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1349.	0.8	0
394	P3â€568: PROGNOSIS OF INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT REVERTING TO NORMAL COGNITION. Alzheimer's and Dementia, 2018, 14, P1341.	0.8	0
395	F1â€02â€02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P201.	0.8	0
396	P3â€355: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P1221.	0.8	0

#	Article	IF	Citations
397	F1â€02â€01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENTâ€LIGHT AND YKLâ€40 TO AÎ², APOE Îµ4 AND COGNITION: RESULTS FROM THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P201.	0.8	0
398	P2â€458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P895.	0.8	0
399	F1â€02â€03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P202.	0.8	0
400	P4â€077: BLOOD INFLAMMATORY PROFILES MEASURED BY THE ADFLAG^{Â®} TEST ENABLE STRATIFICATION OF PREâ€DEMENTIA ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1464.	0.8	0
401	Personality and Dementia. , 2018, , 83-110.		0
402	P4â€525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1515.	0.8	0
403	ICâ€Pâ€015: VOXELâ€BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2019, 15, P24.	0.8	0
404	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. Alzheimer's and Dementia, 2020, 16, e037912.	0.8	0
405	CSF proteomic changes in preâ€preclinical Alzheimerâ€™s disease: A monozygotic twin study. Alzheimer's and Dementia, 2020, 16, e038966.	0.8	0
406	The impact of a nutritional intervention in prodromal Alzheimerâ€™s disease: The LipiDiDiet clinical trial. Alzheimer's and Dementia, 2020, 16, e039846.	0.8	0
407	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. Alzheimer's and Dementia, 2020, 16, e040152.	0.8	0
408	Amygdalar nuclei and hippocampal subfields on MRI: Testâ€retest reliability of automated segmentation in old and young healthy volunteers. Alzheimer's and Dementia, 2020, 16, e040322.	0.8	0
409	General practitionersâ€™ opinion on early and preâ€dementia diagnosis of AD: A MOPEAD project survey in five European countries. Alzheimer's and Dementia, 2020, 16, e040357.	0.8	0
410	Functional interpretation of genetic risk loci for dementia using a protein quantitative trait loci (pQTLs) approach in cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e040774.	0.8	0
411	Amyloidâ€Î² deposition in cognitively normal oldestâ€old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e040991.	0.8	0
412	Research diagnostic criteria for Alzheimerâ€™s disease: Findings from the multinational LipiDiDiet Trial. Alzheimer's and Dementia, 2020, 16, e042530.	0.8	0
413	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e042739.	0.8	0
414	Amyloidâ€Î² deposition in cognitively normal oldestâ€old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e042768.	0.8	0

#	Article	IF	Citations
415	Amyloidâ€dependent association of grey matter network disruptions with phosphoâ€tau in preclinical Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e044739.	0.8	0
416	Amyloid aggregation and subsequent memory decline over time in cognitively intact older identical twins. Alzheimer's and Dementia, 2020, 16, e045112.	0.8	0
417	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in nonâ€demented memory clinic participants. Alzheimer's and Dementia, 2020, 16, e045196.	0.8	0
418	Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals. Alzheimer's and Dementia, 2020, 16, e045470.	0.8	0
419	Plasma amyloidâ€Î² oligomerization assay as a screening test for abnormal amyloid status. Alzheimer's and Dementia, 2020, 16, e045754.	0.8	0
420	DNA methylation differences associated with peripheral biomarkers in the EMIFâ€AD cohort. Alzheimer's and Dementia, 2020, 16, e045853.	0.8	0
421	Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. Alzheimer's and Dementia, 2020, 16, e045876.	0.8	0
422	Synaptic proteins relate to memory scores in preclinical Alzheimerâ€™s disease and cognitively healthy controls depending on amyloid. Alzheimer's and Dementia, 2020, 16, e046102.	0.8	0
423	AB0728â€…MICROVASCULAR CHANGES OF THE RETINA IN ANKYLOSING SPONDYLITIS, AND THE ASSOCIATION WITH CARDIOVASCULAR DISEASE â€“ THE EYE FOR A HEART STUDY.. Annals of the Rheumatic Diseases, 2020, 79, 1658.2-1659.	0.9	0
424	Decorin is an early CSF biomarker of Alzheimerâ€™s AÎ² amyloidosis. Alzheimer's and Dementia, 2021, 17, .	0.8	0
425	Associations between CSF proteins and medial temporal lobe atrophy across the AD continuum. Alzheimer's and Dementia, 2021, 17, .	0.8	0
426	The association between diabetes and Alzheimerâ€™s disease pathophysiology. Alzheimer's and Dementia, 2021, 17, .	0.8	0
427	Mapping associations across multiple aspects of Alzheimer disease and the role of CSF biomarkers in individuals without dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
428	Amyloid discordance analysis in cognitively normal monozygotic twins demonstrates that the memory domain is affected first in preclinical AD. Alzheimer's and Dementia, 2021, 17, .	0.8	0
429	Is A+Tâ€•Alzheimerâ€™s disease or not? A combined CSF and pathology study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
430	Associations of lifestyle factors with amyloid positivity in cognitively normal individuals at different levels of genetic risk: The amyloid biomarker study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
431	Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, .	0.8	0
432	Genetically identical twins are highly similar in levels and spatial distribution of tau pathology: A [¹⁸ F]flortaucipir PET study. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	Article	IF	Citations
433	Alzheimerâ€™s disease genetic risk variants show brain cell typeâ€specific associations with protein levels in cerebrospinal fluid. Alzheimer's and Dementia, 2021, 17, e049531.	0.8	0
434	Current status and quantitative results of the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
435	Plasma Pâ€tau181 levels predict amyloid pathology in cognitively unimpaired individuals after 10 years. Alzheimer's and Dementia, 2021, 17, .	0.8	0
436	Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort. Alzheimer's and Dementia, 2021, 17, .	0.8	0
437	CSF protein panels reflecting multiple pathophysiological mechanisms for early and specific diagnosis of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
438	Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimerâ€™s disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification. Alzheimer's and Dementia, 2021, 17, e053030.	0.8	0
439	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055451.	0.8	0